Literature DB >> 8676509

Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.

S W Ludmerer1, D Benincasa, G E Mark.   

Abstract

Characterization of virus binding by neutralizing antibodies is important both in understanding early events in viral infectivity and in development of vaccines. Neutralizing monoclonal antibodies (MAbs) to human papillomavirus type 11 (HPV11) have been described, but mapping the binding site has been difficult because of the conformational nature of key type-specific neutralization epitopes on the L1 coat protein. We have determined those residues of the L1 protein of HPV11 which confer type specificity to the binding of HPV11-neutralizing MAbs. Binding of three HPV11-specific neutralizing MAbs could be redirected to HPV6 L1 virus-like particles in which as few as two substitutions of corresponding amino acid residues from HPV11 L1 have been made, thus demonstrating the importance of these residues to MAb binding through the transfer of a conformationally dependent epitope. In addition, a fourth neutralizing MAb could be distinguished from the other neutralizing MAbs in terms of the amino acid residues which affect binding, suggesting the possibility that it neutralizes HPV11 through a different mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676509      PMCID: PMC190419     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

Authors:  N D Christensen; R Kirnbauer; J T Schiller; S J Ghim; R Schlegel; A B Jenson; J W Kreider
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

2.  Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D.

Authors:  M I Muggeridge; T T Wu; D C Johnson; J C Glorioso; R J Eisenberg; G H Cohen
Journal:  Virology       Date:  1990-02       Impact factor: 3.616

3.  Rapid, high-level transient expression of papillomavirus-like particles in insect cells.

Authors:  D Benincasa; M Silberklang; G E Mark; S W Ludmerer
Journal:  Biotechniques       Date:  1996-05       Impact factor: 1.993

4.  Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope.

Authors:  S A Jenison; X P Yu; J M Valentine; D A Galloway
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  The nucleotide sequence and genome organization of human papilloma virus type 11.

Authors:  K Dartmann; E Schwarz; L Gissmann; H zur Hausen
Journal:  Virology       Date:  1986-05       Impact factor: 3.616

6.  Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types.

Authors:  W F Jarrett; B W O'Neil; J M Gaukroger; K T Smith; H M Laird; M S Campo
Journal:  Vet Rec       Date:  1990-05-12       Impact factor: 2.695

7.  Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.

Authors:  N D Christensen; C A Reed; N M Cladel
Journal:  Virology       Date:  1995-07-10       Impact factor: 3.616

Review 8.  Human papillomavirus vaccines: a warty problem.

Authors:  D A Galloway
Journal:  Infect Agents Dis       Date:  1994-08

9.  Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata.

Authors:  J W Kreider; M K Howett; S A Wolfe; G L Bartlett; R J Zaino; T Sedlacek; R Mortel
Journal:  Nature       Date:  1985 Oct 17-23       Impact factor: 49.962

10.  DNA sequence and genome organization of genital human papillomavirus type 6b.

Authors:  E Schwarz; M Dürst; C Demankowski; O Lattermann; R Zech; E Wolfsperger; S Suhai; H zur Hausen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  25 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 3.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

5.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

6.  Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.

Authors:  Joseph J Carter; Greg C Wipf; Margaret M Madeleine; Stephen M Schwartz; Laura A Koutsky; Denise A Galloway
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.

Authors:  Joseph J Carter; Greg C Wipf; Sarah F Benki; Neil D Christensen; Denise A Galloway
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.